A Phase 4 interventional study of Nicotine Replacement Therapy (NRT) and Wellness Coaching in Tobacco Cessation, Tobacco Abstinence and Tobacco Use, sponsored by University of California, San Francisco. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-21.
Sponsored by University of California, San Francisco · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Tobacco Use Cessation by University of California, San Francisco — 2 open to participants now, 2 under way, none of them phase 3. Tobacco Use Cessation · University of California, San Francisco.
Among the 11 studies in Tobacco Use Cessation by University of California, San Francisco, this one is the 7th largest by planned enrollment, is one of 2 that started in 2025, is one of 2 in phase 4, and was the 11th registered.
276 studies on the registry are indexed under Tobacco Use Cessation; 45 are open to participants now.
Browse Tobacco Use Cessation studies →2 of the 11 studies in Tobacco Use Cessation by University of California, San Francisco are open now, in 1 country. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+ · Women only · Healthy volunteers
By country, each count listing its studies:
Of the 23 Tobacco Use Cessation studies recruiting now, 16 (70%) set no upper age limit and 6 (26%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 150 is below the median of 226 across 256 interventional studies indexed under Tobacco Use Cessation.
Median enrollment 165 across the 11 interventional studies. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of California, San Francisco is the lead sponsor of 2,172 studies on the registry; 370 are open to participants now.
Of its 269 completed or terminated interventional studies of FDA-regulated products, 203 (75%) have results posted.
2 of the studies in Tobacco Use Cessation by University of California, San Francisco that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07129590University of California, San FranciscoTrauma-Informed Care for Smoking Cessation for Pregnancy | 2026-12-31 |
| NCT07148232University of California, San FranciscoExtended Intervention for Tobacco Use (EXIT) for People Experiencing Homelessness | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Tobacco Use Cessation by University of California, San Francisco, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is investigating tobacco use and providing tobacco treatment among people experiencing homelessness in California, in San Francisco and Los Angeles.
PRIMARY OBJECTIVES:
I. Biochemically verified 7-day point prevalence tobacco abstinence at 6-months follow-up.
II. Use expired carbon monoxide (CO) to confirm self-reports of abstinence using a cut-off of CO ≤5 parts per million (ppm).
SECONDARY OBJECTIVES:
I. Biochemically-verified 7-day point prevalence tobacco abstinence at 3-months follow-up.
II. Measured at 6-months follow-up, a total number of expired carbon monoxide (CO-negative samples).
III. Measured at 6-months follow-up, longest duration of abstinence (i.e., total number of uninterrupted days abstinent), proportion with 50% reduction in expired CO for those who do not quit smoking.
IV. Use expired CO to confirm self-reports of abstinence using a cut-off of CO ≤5 ppm.
OUTLINE:
Participants will be randomized to one of two groups:
Participants will be followed up at 1, 3 and 6 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive pharmacist provided one-time tobacco treatment using the five As: Ask, Advise, Assess, Assist and Arrange (5As) model and receives an initial monthly delivery of nicotine replacement therapy (NRT) for 3 months. Participants then receive the extended intervention for tobacco use (EXIT) that consists of: 1) health coach-delivered, weekly-to-monthly wellness-focused telephone coaching for 6 months addressing tobacco use within the context of co-occurring psychiatric and substance-use comorbidities and other life stressors, and 2) an additional session of pharmacist-delivered 5As with monthly delivery of NRT for an additional 6 months. Participants will provide CO samples for biochemical verification of smoking abstinence and complete questionnaires throughout the study.
Drug: Nicotine Replacement Therapy (NRT) · Behavioral: Wellness Coaching
Participants receive pharmacist provided one-time tobacco treatment using the 5As and receive monthly delivery of NRT for 3 months. Participants will provide CO samples for biochemical verification of smoking abstinence and complete questionnaires throughout the study.
Drug: Nicotine Replacement Therapy (NRT)
NRT will be administered as patch (transdermal), gum, or lozenge
Also known as: NRT
Delivered via phone call
Percentage of participants who attended coaching sessions
The percentage of participants who attended at least 75% or 7 of the 14 coaching sessions will be reported.
Time frame: up to 6 months
Percentage of participants who used nicotine replacement therapy (NRT)
The percentage of participants who used at least 75% will adhere to using NRT for at least half of the treatment duration will be reported.
Time frame: up to 6 months
7-day point prevalence tobacco abstinence at month 6
Biochemically verified 7-day point prevalence tobacco abstinence at 6-months follow-up will be reported.
Time frame: 6 months
7-day point prevalence tobacco abstinence at month 3
Biochemically verified 7-day point prevalence tobacco abstinence at 3-months follow-up will be reported.
Time frame: 3 months
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Jun 2027, 19 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Francisco →